Our pipeline

Target/Product

Indication(s)

Research

Preclinical Development

Clinical Phase 1/2/3

Upcoming Milestones

Porcupine Inhibitor
(RXC004)

Genetically selected MSS mCRC mono + nivolumab combo

Combo: Initiate Phase 2 – 2022
Topline data – H1 2023

Read more

RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as…

Genetically selected pancreatic cancer
Unselected biliary cancer

Initiate Phase 2 – H1 2022
Topline data – H1 2023

Read more

RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as…

ROCK2
Selective Inhibitor
(RXC007)

Idiopathic pulmonary fibrosis (IPF)

Phase 1 topline results – H1 2022
Initiate Phase 2a – 2022

Read more

RXC007 is an orally available, highly selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signalling pathway, believed to be central to fibrosis. ROCK2 is therefore an important emerging drug target and RXC007 has the potential to…

GI-targeted ROCK inhibitor

Fibrosis in Crohn’s

Preclinical development
candidate – H1 2022

Read more

Our GI-targeted ROCK inhibitor is a first-in-class programme designed to treat Crohn’s Disease-associated fibrosis. Up to 50% of patients with Crohn’s disease can develop significant fibrosis and stricture formation within 10 years after diagnosis. The current management of fibrotic strictures of the gastrointestinal (GI) tract is primarily surgical…

DDR Inhibitor

Fibrosis

In lead optimisation

Read more

Discoidin domain receptors (DDRs) were discovered in the 1990’s but more recently they have gained traction as new therapeutic targets with potential to treat multiple fibrotic conditions.

MAPK Pathway
(2 targets)

Oncology

Progress Jazz collaboration

In September 2020, Redx signed a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets on the Ras/Raf/MAP kinase (MAPK) pathway. Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. To date, Redx has  received $20 million in upfront and milestone payments, with potential for up to a further $400 million in milestones, plus tiered royalties.

Porcupine Inhibitor
(RXC006/AZD5055)

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Read more

In August 2020, Redx Pharma signed a significant out licensing agreement for our porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Under the terms of the exclusive global…

Pan-RAF Inhibitor
(JZP815)

Oncology

Sold to Jazz Pharmaceuticals

Read more

Pan-RAF inhibitor sold to Jazz Pharmaceuticals, Pan-RAF inhibitor programme aims to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs. Mutations leading to uncontrolled signalling via the RAS-RAF-MAPK pathway are seen in over one third of all cancers. The RAF kinases (A-RAF, B-RAF and C-RAF) are an integral part of this pathway, with B-RAF mutations commonly seen…

Oncology

Fibrosis

Partnered

MSS mCRC=Microsatellite-Stable Metastatic Colorectal Cancer; IPF=Idiopathic Pulmonary Fibrosis